Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-301 Nasal Spray Safety and PK in Healthy Volunteers
NCT06954428Phase 1Completed
- Sponsor
- Nano PharmaSolutions
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Aporon in Parkinson's disease (PD) (7 arms), sponsored by Nano PharmaSolutions. Primary endpoints: Safety of NT-301 at 7 days and Tolerability of NT-301 at 7 days. Started Jun 2025; status: completed.
02
Drugs
Aporon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06954428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954428.